Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.04 - Poster Session 1 - Tumor Immunology
- Type: Poster Session
- Track: Biology
- Presentations: 1
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.04-001 - Combining Prime-Boost Anti-tumour Vaccination with Debulking Surgery for the Treatment of Malignant Mesothelioma
09:30 - 09:30 | Author(s): S. Fisher
- Abstract
Loading...
-
+
P1.05 - Poster Session 1 - Preclinical Models of Therapeutics/Imaging
- Type: Poster Session
- Track: Biology
- Presentations: 25
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.05-001 - EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition
09:30 - 09:30 | Author(s): S. Takeuchi
- Abstract
Loading... -
+
P1.05-002 - Reversal of Resistance to EGFR tyrosine kinase inhibitor by EGFR T790M specific siRNA in Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): C. Lee
- Abstract
Loading... -
+
P1.05-003 - The PDGFR/Src signaling pathway-targeted therapy with novel TUSC2-nanoparticles and tyrosine kinase inhibitors for human lung cancer
09:30 - 09:30 | Author(s): Q. Wu
- Abstract
Loading... -
+
P1.05-004 - Molecular mechanism of resistance to afatinib in EGFR-mutated non-small cell lung cancer (NSCLC) cell lines and potential therapeutic implications
09:30 - 09:30 | Author(s): F. Grossi
- Abstract
Loading... -
+
P1.05-005 - VEGF signaling inhibition by cediranib enhances the antitumor and anti-metastatic effects of radiation therapy more substantially than chemotherapy in orthotopic lung cancer models
09:30 - 09:30 | Author(s): O. Takahashi
- Abstract
Loading... -
+
P1.05-006 - Targeted delivery of RRM1-specific siRNA leads to tumour growth inhibition in malignant pleural mesothelioma
09:30 - 09:30 | Author(s): G. Reid
- Abstract
Loading... -
+
P1.05-007 - Large scale establishment of genetically diverse patient-derived primary tumor xenografts from resected early stage non-small cell lung cancer (NSCLC) patients
09:30 - 09:30 | Author(s): L. Kim
- Abstract
Loading... -
+
P1.05-008 - The HSP 90 inhibitors suppress cell growth by suppression of ALK and TGF-beta1 signaling in crizotinib-resitant H2228 cells by Epithelial to mesenchymal transition
09:30 - 09:30 | Author(s): H.R. Kim
- Abstract
Loading... -
+
P1.05-009 - Development of small cell lung cancer primary xenografts using specimens obtained by endobronchial-ultrasound transbronchial needle aspiration: a novel pre-clinical model
09:30 - 09:30 | Author(s): T. Leong
- Abstract
Loading... -
+
P1.05-010 - Pre-Clinical validation of Electro-Chemotherapy (ECT) in the treatment of Lung tumours
09:30 - 09:30 | Author(s): S. Jahangeer
- Abstract
Loading... -
+
P1.05-011 - Antitumor agent KNG-I-484C causes cell death through inducing cell cycle arrest
09:30 - 09:30 | Author(s): T. Che
- Abstract
Loading... -
+
P1.05-012 - The HSP90 inhibitor, AT13387, displays single agent activity in erlotinib-sensitive and -resistant models of EGFR-activated NSCLC
09:30 - 09:30 | Author(s): K. Hearn
- Abstract
Loading... -
+
P1.05-013 - Apoptosis-targeted drug and T-cell delivery to lung cancer
09:30 - 09:30 | Author(s): K.U. Park
- Abstract
Loading... -
+
P1.05-014 - Cancer Stem Cell-like Population from Non-Small Cell Lung Cancer is Preferentially Suppressed by EGFR-TKIs
09:30 - 09:30 | Author(s): Q. Zhou
- Abstract
Loading... -
+
P1.05-015 - Assessment of the activity of Pemetrexed and Dasatinib as single agents and in combination in three malignant pleural mesothelioma cell lines
09:30 - 09:30 | Author(s): V. Monica
- Abstract
Loading... -
+
P1.05-016 - EphB4 Receptor Kinase, a Novel Therapeutic Target for Lung Cancer
09:30 - 09:30 | Author(s): B. Gitlitz
- Abstract
Loading... -
+
P1.05-017 - Ascorbic acid and AHCC suppress lung fibrosis and cancer caused by irradiation
09:30 - 09:30 | Author(s): T. Hongyo
- Abstract
Loading... -
+
P1.05-018 - Inhibition of Non-small-cell Lung Cancer Growth by pH Control Release Nanoparticle Carrying miR-135b Antagomir
09:30 - 09:30 | Author(s): C. Lin
- Abstract
Loading... -
+
P1.05-019 - JNJ-42756493 is a potent and selective FGFR1-4 kinase inhibitor with promise for clinical use in patients with FGFR driven tumors
09:30 - 09:30 | Author(s): T.P.S. Perera
- Abstract
Loading... -
+
P1.05-020 - Identifying therapeutic targets for mesothelioma using siRNA
09:30 - 09:30 | Author(s): E. Sollis
- Abstract
Loading... -
+
P1.05-021 - Dual checkpoint blockade using anti-PD-1 and anti-CTLA4 combined with cisplatin chemotherapy is effective in a murine mesothelioma model
09:30 - 09:30 | Author(s): A. Khong
- Abstract
Loading... -
+
P1.05-022 - BET Bromodomains: Are they a potential therapeutic targets in Malignant Pleural Mesothelioma?
09:30 - 09:30 | Author(s): C. Albadri
- Abstract
Loading... -
+
P1.05-023 - The KDM4/JMJD2 Lysine Demethylases are candidate therapeutic targets in Malignant Pleural Mesothelioma
09:30 - 09:30 | Author(s): M. Breslin
- Abstract
Loading... -
+
P1.05-024 - PARP inhibition increases sensitivity of NSCLC cells to cisplatin
09:30 - 09:30 | Author(s): R. Rausch
- Abstract
Loading... -
+
P1.05-025 - EGFR blockade increases lung cancer stem cell-like cells by upregulation of Notch3 signaling.
09:30 - 09:30 | Author(s): R.R. Arasada
- Abstract
Loading...
-
+
P1.06 - Poster Session 1 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 59
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.06-001 - HDL-Cholesterol is Reduced in Advanced Stage Lung Cancer Patients With Weight Loss
09:30 - 09:30 | Author(s): B. Karagoz
- Abstract
Loading... -
+
P1.06-002 - Intratumor variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer
09:30 - 09:30 | Author(s): J.N. Jakobsen
- Abstract
Loading... -
+
P1.06-003 - Comparative effectiveness of ddPCR for the detection of EGFR mutations.
09:30 - 09:30 | Author(s): M. Daniels
- Abstract
Loading... -
+
P1.06-004 - ROS1 Immunohistochemistry Among Major Genotypes of Non-Small Cell Lung Carcinoma
09:30 - 09:30 | Author(s): T. Boyle
- Abstract
Loading... -
+
P1.06-005 - The Clinical Significance of Serum BAP, TRACP 5b and ICTP as Bone Metabolic Markers for Bone Metastasis Screening in Lung Cancer Patients
09:30 - 09:30 | Author(s): C. Tang
- Abstract
Loading... -
+
P1.06-006 - Prognostic value of serial peripheral circulating tumour cells (CTC) evaluation in patients with advanced non-small cell lung cancer (NSCLC) during first line treatment.
09:30 - 09:30 | Author(s): J.L. Gonzalez Larriba
- Abstract
Loading... -
+
P1.06-007 - Relationship between 5FU related enzymes and EGFR mutation status in non-small cell lung cancer treated with S-1 adjuvant therapy
09:30 - 09:30 | Author(s): K. Mochinaga
- Abstract
Loading... -
+
P1.06-008 - Expression of PTRF/Cavin-1 is associated with poor prognosis of lung adenocarcinoma
09:30 - 09:30 | Author(s): H. Inoue
- Abstract
Loading... -
+
P1.06-009 - Expression of BMP-7 in non-small cell lung cancer and its clinical significance
09:30 - 09:30 | Author(s): M. Aoki
- Abstract
Loading... -
+
P1.06-010 - Expression of α1,6-fucosyltransferase is associated with prognosis and histology in non-small cell lung cancers
09:30 - 09:30 | Author(s): R. Honma
- Abstract
Loading... -
+
P1.06-011 - Next generation sequencing in lung cancers - focusing on the kinome
09:30 - 09:30 | Author(s): Å. Helland
- Abstract
Loading... -
+
P1.06-012 - A disintegrin and metalloproteinase-9 is highly expressed, correlated with lymph nodes metastasis, predicts worse prognosis and may help improving personalized postoperative treatment in resected non-small cell lung cancer
09:30 - 09:30 | Author(s): J. Zhang
- Abstract
Loading... -
+
P1.06-013 - Detection of Circulating Tumour Cells in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): M. Fanning
- Abstract
Loading... -
+
P1.06-014 - A nomogram for predicting 5-year RFS in patients with pulmonary carcinoid tumors incorporating Ki-67 and clinical variables
09:30 - 09:30 | Author(s): T. Reungwetwattana
- Abstract
Loading... -
+
P1.06-015 - EGFR mutated patients: different pattern and outcome of metastatic bone disease and brain metastases?
09:30 - 09:30 | Author(s): L. Hendriks
- Abstract
Loading... -
+
P1.06-016 - Anaplastic Lymphoma kinase (ALK) alterations by FISH in a cohort of Spanish Non-Small Cell Lung Cancer (NSCLC) patients analysed in a certified centre of reference
09:30 - 09:30 | Author(s): J. Vidal
- Abstract
Loading... -
+
P1.06-017 - Targeted proteomics and HT-IHC for lung cancer biomarker studies.
09:30 - 09:30 | Author(s): Y.J. Kim
- Abstract
Loading... -
+
P1.06-018 - Cumalative Biomarker Model Predicts 3-Year Recurrence in Resected Stage I Adenocarcinoma of the Lung
09:30 - 09:30 | Author(s): J. Donington
- Abstract
Loading... -
+
P1.06-019 - Common and uncommon EGFR mutations and their impact on response to EGFR tyrosine-kinase inhibitors and platinum-based chemotherapy in non-small cell lung cancer (NSCLC): Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)
09:30 - 09:30 | Author(s): O. Arrieta
- Abstract
Loading... -
+
P1.06-020 - Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine carcinomas of the lung
09:30 - 09:30 | Author(s): A. Takahashi
- Abstract
Loading... -
+
P1.06-021 - Validation of DNA Hypermethylation Analysis in Sputum for the Diagnosis of Lung Cancer
09:30 - 09:30 | Author(s): A.J. Hubers
- Abstract
Loading... -
+
P1.06-022 - Investigating the utility of plasma derived circulating free DNA for the detection of epidermal growth factor receptor (EGFR) mutations in European and Japanese patients with advanced non-small-cell lung cancer (NSCLC): ASSESS study design
09:30 - 09:30 | Author(s): M. Reck
- Abstract
Loading... -
+
P1.06-023 - Anaplastic Lymphoma Kinase (ALK)-detection in Non-small Cell Lung Cancer: results of the first European IHC-based (D5F3-Optiview) panel test within 16 institutes
09:30 - 09:30 | Author(s): M. Von Laffert
- Abstract
Loading... -
+
P1.06-024 - FAM83B, a novel molecular target for lung squamous cell carcinoma.
09:30 - 09:30 | Author(s): N. Okabe
- Abstract
Loading... -
+
P1.06-025 - Determination of the activity of lysosomal enzymes and protease inhibitors is useful in the diagnostics of lung cancer.
09:30 - 09:30 | Author(s): P. Bławat
- Abstract
Loading... -
+
P1.06-026 - Validation of a Proliferation-based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma
09:30 - 09:30 | Author(s): R. Bueno
- Abstract
Loading... -
+
P1.06-027 - Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy
09:30 - 09:30 | Author(s): S.Y. Lee
- Abstract
Loading... -
+
P1.06-028 - Droplet digital PCR: A novel detection method of activating Epidermal Growth Factor Receptor (EGFR) mutations in plasma of patients with advanced stage non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): C.K.M. Lee
- Abstract
Loading... -
+
P1.06-029 - Serum nitric oxide could be a predictor for the response of bevacizumab in patients with non-small cell lung cancer
09:30 - 09:30 | Author(s): S. Muto
- Abstract
Loading... -
+
P1.06-030 - KRAS mutations in resectable NSCLC patients. Prognostic implications.
09:30 - 09:30 | Author(s): S. Gallach
- Abstract
Loading... -
+
P1.06-031 - Is there any role for monitoring circulating tumor cells (CTC) in stage III non-small-cell lung cancer (NSCLC) patients?
09:30 - 09:30 | Author(s): P. Garrido
- Abstract
Loading... -
+
P1.06-032 - The high protein expression of EGFR using a specific internal domain antibody and loss of PTEN can be used as predictive factors for EGFR TKIs in patients with advanced squamous cell lung cancer
09:30 - 09:30 | Author(s): J. Oh
- Abstract
Loading... -
+
P1.06-033 - The impact of plasma levels of Vascular Endothelial Growth Factor receptor 2(VEGF R2) and Hepatocyte Growth Factor (HGF) on survival in long-term survivors with advanced lung cancer (ALCP)
09:30 - 09:30 | Author(s): Z. Mihaylova
- Abstract
Loading... -
+
P1.06-034 - MET expression, copy number and oncogenic mutations in early stage NSCLC
09:30 - 09:30 | Author(s): T. John
- Abstract
Loading... -
+
P1.06-035 - VEGF-A 165 family of isoforms as predictive biomarkers in patients with non-squamous non-small cell lung cancer (NSCLC) treated with bevacizumab.
09:30 - 09:30 | Author(s): M. Domine
- Abstract
Loading... -
+
P1.06-036 - Relationship between Serum Sodium Levels and Tumor characteristics in Non-Small Cell Lung Cancer.
09:30 - 09:30 | Author(s): A. Kumar
- Abstract
Loading... -
+
P1.06-037 - Angiopoietin-2 serum and mRNA levels as prognostic factors in Non Small Cell Lung cancer
09:30 - 09:30 | Author(s): A. Coelho
- Abstract
Loading... -
+
P1.06-038 - Single Cell Genomic Analyses of Circulating Tumor Cells from Lung Cancer Patients
09:30 - 09:30 | Author(s): X. Ni
- Abstract
Loading... -
+
P1.06-039 - Impact of Ki-67 labeling index as a predictive marker for chemotherapy in non-small cell lung cancer
09:30 - 09:30 | Author(s): Y. Hirai
- Abstract
Loading... -
+
P1.06-040 - The Bim Deletion Polymorphism profile and its relationship with TKIs Resistance in Chinese NSCLC Population
09:30 - 09:30 | Author(s): Y. Zhang
- Abstract
Loading... -
+
P1.06-041 - Prognostic impact of cytoskeleton regulatory protein human Mena (hMena) isoforms in resected, node-negative, non-small-cell lung cancer: validation of a clinic-molecular prognostic model.
09:30 - 09:30 | Author(s): E. Bria
- Abstract
Loading... -
+
P1.06-042 - Klotho expression in patients having EGFR mutations (CLICaP study)
09:30 - 09:30 | Author(s): C. Vargas
- Abstract
Loading... -
+
P1.06-043 - Pharmacogenetic study in advanced non-small cell lung cancer patients treated with platinum based chemotherapy.
09:30 - 09:30 | Author(s): I.G. Sullivan
- Abstract
Loading... -
+
P1.06-044 - Diagnostic validation of PNA-LNA PCR clamp assay for detection of EGFR exon 19 and 21 mutations in non-small cell lung cancer specimens.
09:30 - 09:30 | Author(s): M. Skronski
- Abstract
Loading... -
+
P1.06-045 - Serum microRNA as a predictive marker for radiation pneumonitis in patients with inoperable/unresectablenon-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): N. Bi
- Abstract
Loading... -
+
P1.06-046 - Prognostic Relevance of the Quantification of Circulating Tumor Cells by mean Epithelial Markers in Advanced Non-Small Cell Lung Cancer Patients.
09:30 - 09:30 | Author(s): S. Muniz-Hernandez
- Abstract
Loading... -
+
P1.06-047 - Tumor expression of TTF1 is associated with a doubling of overall survival in patients with advanced lung adenocarcinomas
09:30 - 09:30 | Author(s): M.D. Hellmann
- Abstract
Loading... -
+
P1.06-048 - An extensive analysis on T1aN0 non-small cell lung cancer: from surgery to pathology.
09:30 - 09:30 | Author(s): P. Bertoglio
- Abstract
Loading... -
+
P1.06-049 - Analysis of Tn antigen and its relationship with clinic, histologic and biomarkers profile in patients with non-small-cell lung cancer (NSCLC).
09:30 - 09:30 | Author(s): D. Touya
- Abstract
Loading... -
+
P1.06-050 - Cost-Effectiveness of the Pervenio™ Risk-Score (RS) Assay in Early-Stage Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): J.A. Roth
- Abstract
Loading... -
+
P1.06-051 - Development of a serum biomarker panel predicting clinical outcome of chemotherapy with pemetrexed in patients with NSCLC
09:30 - 09:30 | Author(s): J.A. Borgia
- Abstract
Loading... -
+
P1.06-052 - Biomarkers of phenotypic plasticity associated with clinical outcomes in patients with locally-advanced NSCLC treated with chemoradiation with and without surgery.
09:30 - 09:30 | Author(s): M. Batus
- Abstract
Loading... -
+
P1.06-053 - Clinical utility of circulating serum and plasma biomarkers for personalised radiotherapy treatment of non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): C. Faivre-Finn
- Abstract
Loading... -
+
P1.06-054 - Targeting MCL1 amplification in NSCLC through anthracycline-mediated transcriptional suppression
09:30 - 09:30 | Author(s): S. Busacca
- Abstract
Loading... -
+
P1.06-055 - The RON (MST1R)/MSP pathway is a potential therapeutic target in malignant plural mesothelioma
09:30 - 09:30 | Author(s): A. Baird
- Abstract
Loading... -
+
P1.06-056 - Isolation & enumeration of Circulating Tumor Cells in Non-small Cell Lung Cancer, using Screencell & VitaAssay techniques.
09:30 - 09:30 | Author(s): J. O'Flaherty
- Abstract
Loading... -
+
P1.06-057 - Incidence and significance of tumor EGFR and KRAS mutations in Greek metastatic non-small cell lung cancer patients treated with 1st line chemotherapy.
09:30 - 09:30 | Author(s): H. Linardou
- Abstract
Loading... -
+
P1.06-058 - The PHALCIS Trial (PHarmacogenomic ALimta CISplatin): A clinical trial in progress by The Spanish Lung Cancer Group
09:30 - 09:30 | Author(s): J. Sanchez-Torres
- Abstract
Loading... -
+
P1.06-059 - Comparison of the characteristics and clinical course of patients with metastatic KRAS mutant lung cancers
09:30 - 09:30 | Author(s): G. Riely
- Abstract
Loading...
-
+
P1.07 - Poster Session 1 - Surgery
- Type: Poster Session
- Track: Surgery
- Presentations: 48
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.07-001 - The impact of combined pulmonary fibrosis and chronic obstructive pulmonary disease on long-term survival after lung cancer surgery
09:30 - 09:30 | Author(s): Y. Sekine
- Abstract
Loading... -
+
P1.07-002 - Effect of synchronous solitary bone metastasectomy on resectable non-small cell lung cancer patients
09:30 - 09:30 | Author(s): T. Zhao
- Abstract
Loading... -
+
P1.07-003 - Surgical indication for elderly lung cancer patients according depending on the mortality rate by due to other disease
09:30 - 09:30 | Author(s): M. Kataoka
- Abstract
Loading... -
+
P1.07-004 - Multimodality management and surgical outcomes following post neo-adjuvant chemotherapy, radical chest wall resection and reconstruction for PNET chest wall
09:30 - 09:30 | Author(s): S. Deo
- Abstract
Loading... -
+
P1.07-005 - Length of disease free survival interval is an independent predictive prognostic factor for postrecurrent survival in NSCLC
09:30 - 09:30 | Author(s): M. Kato
- Abstract
Loading... -
+
P1.07-006 - Lung cancer resection in patients with chronic renal failure on hemodialysis
09:30 - 09:30 | Author(s): Y. Kato
- Abstract
Loading... -
+
P1.07-007 - Intrapleural administration of a combination of cisplatin and fibrin glue for pleural lavage cytology-positive patients with non-small cell lung cancer
09:30 - 09:30 | Author(s): H. Shinohara
- Abstract
Loading... -
+
P1.07-008 - The application of SOFT COAG in combination with Triangle-Tensioning for VATS lobectomy and segmentectomy
09:30 - 09:30 | Author(s): T. Sakuragi
- Abstract
Loading... -
+
P1.07-009 - Preoperative simulation and navigation using the combination of high-speed 3D-image analysis system and Robotic surgery increase the efficacy and accuracy in thoracic surgery
09:30 - 09:30 | Author(s): N. Kajiwara
- Abstract
Loading... -
+
P1.07-010 - Preoperative Flourodeoxyglucose-Positron Emission Tomography Scan with Positive N1 Disease Does Not Predict Worse Survival in Pathologic Stage II Patients
09:30 - 09:30 | Author(s): M.P. Kim
- Abstract
Loading... -
+
P1.07-011 - Examination of the relevance of prolonged pulmonary fistula after pulmonary resection for lung cancer and factors about delayed wound healing
09:30 - 09:30 | Author(s): K. Nagano
- Abstract
Loading... -
+
P1.07-012 - Collaborative multimodal pain management strategy for patients with non-small cell lung cancer submitted to thoracotomy
09:30 - 09:30 | Author(s): J.J. Fibla
- Abstract
Loading... -
+
P1.07-013 - "Minimally invasive small incision, muscle- and rib-sparing thoracotomy, minimally invasive lung cancer radical surgery", cures "aging, cardiopulmonary dysfunction patients with lung cancer"
09:30 - 09:30 | Author(s): J. Zhang
- Abstract
Loading... -
+
P1.07-014 - Effect of Advanced Age on Peri-Operative Outcomes after Robotic-Assisted Pulmonary Lobectomy: Retrospective Analysis of 180 Consecutive Cases
09:30 - 09:30 | Author(s): W.W. Zhang
- Abstract
Loading... -
+
P1.07-015 - Dysphagia palliation in locally advanced carcinoma esophagus: Role of Intraluminal brachytherapy.
09:30 - 09:30 | Author(s): M.K. Behera
- Abstract
Loading... -
+
P1.07-016 - Does the utilization of staplers for the interlobar fissures dissection really affect postoperative respiratory function?
09:30 - 09:30 | Author(s): M. Yanada
- Abstract
Loading... -
+
P1.07-017 - Prognostic impact of cytoreductive surgery for non-small cell lung cancer with malignant pleural effusion detected at surgery
09:30 - 09:30 | Author(s): Y. Taniguchi
- Abstract
Loading... -
+
P1.07-018 - Surgical Treatment for Super-elderly Patients ( over 85 years old ) with Lung Cancer
09:30 - 09:30 | Author(s): O. Kawashima
- Abstract
Loading... -
+
P1.07-019 - Is VATS Lobectomy Too Expensive? A Cost Analyze of Introducing VATS Lobectomy to a Tertiary Care Hospital
09:30 - 09:30 | Author(s): D.G. French
- Abstract
Loading... -
+
P1.07-020 - Thoracoscore and European Society Objective Score Do Not Predict Mortality in The UK Population - Is It Time For a New Risk Model?
09:30 - 09:30 | Author(s): A.J. Sharkey
- Abstract
Loading... -
+
P1.07-021 - The risk factor of late recurrence in patients with completely resected non-small cell lung cancer
09:30 - 09:30 | Author(s): Y. Kobayashi
- Abstract
Loading... -
+
P1.07-022 - Results of study evaluating inflammatory biochemical parameters and oxidative stress in patients undergoing VATS and open lobectomy for early stage NSCLC.
09:30 - 09:30 | Author(s): I. Silins
- Abstract
Loading... -
+
P1.07-023 - Direct projection of three dimensional volume analyzed CT images to the surgical field by the portable digital light processing projector for assisting minimally invasive thoracic surgery
09:30 - 09:30 | Author(s): T. Anayama
- Abstract
Loading... -
+
P1.07-024 - Surgical outcome of elderly patients with non-small cell lung carcinoma
09:30 - 09:30 | Author(s): T. Gudbjartsson
- Abstract
Loading... -
+
P1.07-025 - Long-term Survival of Patients with cN2/pN2 Non-Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): S. Jheon
- Abstract
Loading... -
+
P1.07-026 - VATS reduces surgical risk of lobectomy for high risk patients with early non-small cell lung cancer
09:30 - 09:30 | Author(s): M. De Valence
- Abstract
Loading... -
+
P1.07-027 - VATS lobectomy for non-small cell lung cancer in patients with severe COPD
09:30 - 09:30 | Author(s): W. Wang
- Abstract
Loading... -
+
P1.07-028 - Thoracoscopic minimally invasive surgery for non-small cell lung cancer in patients with chronic obstructive pulmonary disease
09:30 - 09:30 | Author(s): F. Cui
- Abstract
Loading... -
+
P1.07-029 - Nomogram for predicting survival in patients with resected non-small cell lung cancer
09:30 - 09:30 | Author(s): W. Liang
- Abstract
Loading... -
+
P1.07-030 - Prognostic factors for patients in brain metastasis with no extracranial metastasis after resection of non-small cell lung cancer
09:30 - 09:30 | Author(s): M.K. Bae
- Abstract
Loading... -
+
P1.07-031 - Is lymph node dissection at station 11s necessary in primary lung cancer located in the middle lobe?
09:30 - 09:30 | Author(s): R. Kawachi
- Abstract
Loading... -
+
P1.07-032 - Experience of surgical treatment of myasthenia
09:30 - 09:30 | Author(s): A. Kasatov
- Abstract
Loading... -
+
P1.07-033 - Video-Assisted Thoracoscopic Surgery (VATS) Lobectomy: A Consensus Statement
09:30 - 09:30 | Author(s): T.D. Yan
- Abstract
Loading... -
+
P1.07-034 - Number of Metastatic Lymph Nodes and Metastatic Lymph Node Ratio Predict Patient Survival in Resected Non-small Cell Lung Cancer
09:30 - 09:30 | Author(s): S. Sato
- Abstract
Loading... -
+
P1.07-035 - Uncertain Resection due to incomplete intraoperative nodal assessment
09:30 - 09:30 | Author(s): T. Yamamoto
- Abstract
Loading... -
+
P1.07-036 - Is radiotherapy unavoidable for N2 disease in NSCLC
09:30 - 09:30 | Author(s): G. Karimundackal
- Abstract
Loading... -
+
P1.07-037 - Clinical characteristics of completely resected lung cancer with combined pulmonary fibrosis and emphysema
09:30 - 09:30 | Author(s): J. Osawa
- Abstract
Loading... -
+
P1.07-038 - Surgical Treatment for T4 Non-small Cell Lung Cancer Invading Mediastinal Structures
09:30 - 09:30 | Author(s): H. Lee
- Abstract
Loading... -
+
P1.07-039 - Predictors of one year survival after lung cancer surgery
09:30 - 09:30 | Author(s): S. Colquist
- Abstract
Loading... -
+
P1.07-040 - Outcomes of Surgical Treatment for Isolated Adrenal Metastasis in Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis
09:30 - 09:30 | Author(s): X. Gao
- Abstract
Loading... -
+
P1.07-041 - Characteristics of a North American Patient Population with the Diagnosis of "Bronchioloalveolar Carcinoma (BAC)"
09:30 - 09:30 | Author(s): C.L. Wilshire
- Abstract
Loading... -
+
P1.07-042 - Video-assisted thoracic surgery lobectomy for unexpected pathologic N2 non-small cell lung cancer
09:30 - 09:30 | Author(s): W.Y. Zhou
- Abstract
Loading... -
+
P1.07-043 - Surgical management of Left Non-Small-Cell Lung Cancer with ipsilateral and contralateral mediastinal node metastasis (N2 and N3α disease) by Systemic extended bilateral mediastinal dissection (Hata's method)
09:30 - 09:30 | Author(s): T. Yokota
- Abstract
Loading... -
+
P1.07-044 - Effects of preoperative rehabilitation on outcome of patients with thoracic tumors and borderline abnormal spirometry results
09:30 - 09:30 | Author(s): O. Glogowska
- Abstract
Loading... -
+
P1.07-045 - Prognostic Implications of Blood Tests Performed Routinely Prior to Surgical Resection of Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): M.O. Smith
- Abstract
Loading... -
+
P1.07-046 - clinical and pathological profile of lung carcinoid
09:30 - 09:30 | Author(s): T. Hermida
- Abstract
Loading... -
+
P1.07-047 - Could video-assisted thoracoscopic lobectomy plus mediastinal lymph node dissection be performed for non-small cell lung cancer in a low-volume hospital?
09:30 - 09:30 | Author(s): Y. Ding
- Abstract
Loading... -
+
P1.07-048 - Learning curve for video-assisted thoracoscopic Surgery lobectomy plus mediastinal lymph node dissection for non-small cell lung cancer: How many cases are needed to reach competence with guidance of consultant surgeon?
09:30 - 09:30 | Author(s): H. Wang
- Abstract
Loading...
-
+
P1.08 - Poster Session 1 - Radiotherapy
- Type: Poster Session
- Track: Radiation Oncology + Radiotherapy
- Presentations: 27
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.08-001 - Correlation of intra-fraction displacement of the mediastinal metastatic lymph nodes with primary tumor, lung and heart based on 4DCT in non-small cell lung cancer
09:30 - 09:30 | Author(s): S.Z. Wang
- Abstract
Loading... -
+
P1.08-002 - Relation of tumor response to radiation dose distribution in locally advanced non-small cell lung cancer undergoing concurrent chemoradiotherapy
09:30 - 09:30 | Author(s): W.S. Yoon
- Abstract
Loading... -
+
P1.08-003 - I Love a Sunburnt Country ... Tripartite Collaborative Approaches to Bringing Stereotactic Ablative Body Radiotherapy (SABR) Lung to the People of Regional Australia
09:30 - 09:30 | Author(s): F. Hegi-Johnson
- Abstract
Loading... -
+
P1.08-004 - Australian Implementation of VMAT for stereotactic body radiotherapy in early lung cancer lung: Comparing VMAT with Coplanar and Non-coplanar Intensity Modulated Radiotherapy and 3D-Conformal Radiotherapy.
09:30 - 09:30 | Author(s): F. Hegi-Johnson
- Abstract
Loading... -
+
P1.08-005 - Active Breathing Coordination to measure tumour motion in lung cancer patients: A feasibility study
09:30 - 09:30 | Author(s): S.S. Kumar
- Abstract
Loading... -
+
P1.08-006 - Inter-observer variability of GTV delineation based on Lung MRI: impact of radiologist led workshop
09:30 - 09:30 | Author(s): S. Kumar
- Abstract
Loading... -
+
P1.08-007 - Outcomes and prognostic factors of stage I non-small cell lung cancer patients treated with stereotactic body radiotherapy or 3-dimentional conformal radiotherapy.
09:30 - 09:30 | Author(s): I. Soda
- Abstract
Loading... -
+
P1.08-008 - Prognostic factors in patients with brain metastasis from non-small cell lung cancer treated with whole-brain radiotherapy
09:30 - 09:30 | Author(s): H. Harada
- Abstract
Loading... -
+
P1.08-009 - Dynamic Tumor Tracking Radiotherapy with Real-Time Monitoring using Vero4DRT
09:30 - 09:30 | Author(s): Y. Matsuo
- Abstract
Loading... -
+
P1.08-010 - NSCLC and radiation pneumonitis post radiotherapy
09:30 - 09:30 | Author(s): S. Brown
- Abstract
Loading... -
+
P1.08-011 - Dosimetric Predictors of Esophageal Toxicity in Patients with Non-small Cell Lung Cancer Receiving Chemotherapy and Radiotherapy
09:30 - 09:30 | Author(s): A.A. Konski
- Abstract
Loading... -
+
P1.08-012 - Significant association between radiation induced oesophagitis, neutropenia and V20 in patients with non-small cell lung cancer
09:30 - 09:30 | Author(s): S. Everitt
- Abstract
Loading... -
+
P1.08-013 - Stereotactic Ablative Radiotherapy of Early Stage Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): J. Cvek
- Abstract
Loading... -
+
P1.08-014 - PET-based radiotherapy planning is highly cost-effective compared to CT-based planning: a model-based evaluation.
09:30 - 09:30 | Author(s): M.L. Bongers
- Abstract
Loading... -
+
P1.08-015 - Comparision of Once-daily vs Twice-daily Thoracic Radiotherapy Outcomes in Limited Disease Small Cell Lung Cancer Treated Concurrently With Cisplatin and Etoposide : A Single Institution Retrospective Analysis
09:30 - 09:30 | Author(s): S. Jeong
- Abstract
Loading... -
+
P1.08-016 - Does lung stereotactic body radiation therapy affect lung membrane diffusion?
09:30 - 09:30 | Author(s): S. Mehiri
- Abstract
Loading... -
+
P1.08-017 - Factors Influencing Utilization of Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer
09:30 - 09:30 | Author(s): A.J. Wu
- Abstract
Loading... -
+
P1.08-018 - Postoperative radiotherapy in T3N0 non-small-cell lung cancer: prognostic value of tumor size and costal pleural invasion
09:30 - 09:30 | Author(s): Y. Choi
- Abstract
Loading... -
+
P1.08-019 - Late Radiographic Changes After Lung Stereotactic Body Radiotherapy: Piloting a Recurrence Scale and a Synoptic Reporting Scale
09:30 - 09:30 | Author(s): H. Raziee
- Abstract
Loading... -
+
P1.08-020 - Stereotactic Ablative Radiotherapy for Pulmonary Oligometastasis from Hepatocellular Carcinoma
09:30 - 09:30 | Author(s): S.Y. Song
- Abstract
Loading... -
+
P1.08-021 - Outcomes of Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer and Pulmonary Metastases.
09:30 - 09:30 | Author(s): F. Hegi-Johnson
- Abstract
Loading... -
+
P1.08-022 - Number of pathologic nodes in regions closest to the oesophagus is the strongest predictor for esophagitis in small cell lung cancer patients treated with concurrent chemo-radiation: an analysis of 170 patients.
09:30 - 09:30 | Author(s): B. Reymen
- Abstract
Loading... -
+
P1.08-023 - How to Minimize the Uncertainties of Internal Target Volume in 4DCT Scans for Stereotactic Body Radiation Therapy of Early Stage Non-small Cell Lung Cancer
09:30 - 09:30 | Author(s): X. Sun
- Abstract
Loading... -
+
P1.08-024 - Functional imaging for normal lung avoidance with proton radiotherapy
09:30 - 09:30 | Author(s): M. Nyflot
- Abstract
Loading... -
+
P1.08-025 - How to Determine Internal Margin for Clinical Practice? - A Study of 44 Lung Cancer cases with 4D-CT Imaging.
09:30 - 09:30 | Author(s): M. Chen
- Abstract
Loading... -
+
P1.08-026 - Functional dosimetric metrics based on the ventilation and perfusion SPECT-CT during the course of radiotherapy and association with radiation-induced lung toxicity in patients with non-small-cell lung cancer
09:30 - 09:30 | Author(s): F. Peng
- Abstract
Loading... -
+
P1.08-027 - Is there a benefit of lung stereotactic ablative radiotherapy (SABR) in our patients with multiple co-morbidities?: Age-adjusted Charlson Comorbidity Index (ACCI) as a predictor of survival in medically inoperable early stage Non Small Cell Lung Cancer patients treated with definitive radiotherapy
09:30 - 09:30 | Author(s): J.R. Pantarotto
- Abstract
Loading...
-
+
P1.09 - Poster Session 1 - Combined Modality
- Type: Poster Session
- Track: Combined Modality
- Presentations: 22
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.09-001 - Induction therapy for patients with potentially unresectable NSCLC (adenocarcinoma). Preliminary result.
09:30 - 09:30 | Author(s): I. Polyakov
- Abstract
Loading... -
+
P1.09-002 - Preoperative chemotherapy regimens for locally advanced stage III non-small cell lung carcinoma:
Downstaging depending on histology, age, chemotherapy protocol09:30 - 09:30 | Author(s): M. Bachoor
- Abstract
Loading... -
+
P1.09-003 - Prognostic impact of secondary pathologic findings on the outcome of patients with resected locally advanced non-small cell lung cancer previously treated with inductive chemotherapy or chemoradiation
09:30 - 09:30 | Author(s): D. Marquez-Medina
- Abstract
Loading... -
+
P1.09-004 - Feasibility and efficacy of inductive chemo or chemoradiation for patients with locally advanced non-small cell lung cancers and reduced respiratory function
09:30 - 09:30 | Author(s): D. Marquez-Medina
- Abstract
Loading... -
+
P1.09-005 - The optimal timing of SRS add to EGFR-TKI treatment for brain metastasis from activating EGFR mutant NSCLC
09:30 - 09:30 | Author(s): H.J. Kim
- Abstract
Loading... -
+
P1.09-006 - Chemo-Radiotherapy For Locally Advanced NSCLC In Resource Limited Population: Is It Isoeffective?
09:30 - 09:30 | Author(s): J.P. Agarwal
- Abstract
Loading... -
+
P1.09-007 - Prognostic Value of Number of Chemotherapy Cycle in Stage IIIB Non-small Cell Lung Cancer Patients Treated with Thoracic Radiotherapy and Concurrent Cisplatin-Vinorelbine
09:30 - 09:30 | Author(s): E. Topkan
- Abstract
Loading... -
+
P1.09-008 - Outcomes in a single institution series of patients with Stage III non-small cell lung carcinoma treated with curative-intent radiotherapy and concurrent carboplatin and paclitaxel chemotherapy.
09:30 - 09:30 | Author(s): H. Trinh
- Abstract
Loading... -
+
P1.09-009 - Preliminary Safety and Treatment Delivery Data During Concurrent Phase of Chemoradiation Therapy of the PROCLAIM Trial: A Phase 3 Trial of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Stage III Nonsquamous Cell Lung Cancer.
09:30 - 09:30 | Author(s): E. Vokes
- Abstract
Loading... -
+
P1.09-010 - Impact of the presence of EGFR mutation on the definitive chemoradiotherapy in patients with locally advanced non-small cell lung cancer: pattern of relapses and survival analyses in 198 patients
09:30 - 09:30 | Author(s): H. Horinouchi
- Abstract
Loading... -
+
P1.09-011 - Phase I clinical trial assessing the MEK inhibitor selumetinib (AZD6244; ARRY-142886) with concomitant thoracic radiotherapy (RT) in patients with Stage III-IV non small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): A. Fusi
- Abstract
Loading... -
+
P1.09-012 - Pemetrexed as first-line treatment in combination with early radiotherapy in advanced non-squamous non-small cell lung cancer: a retrospective analysis
09:30 - 09:30 | Author(s): X. Cai
- Abstract
Loading... -
+
P1.09-013 - Thoracic multidisciplinary clinic (TMDC) and the treatment of stage III non-small cell lung cancer
09:30 - 09:30 | Author(s): E.L. Friedman
- Abstract
Loading... -
+
P1.09-014 - Prognostic Value of Age in Patients Receiving Concurrent Chemoradiotherapy with Diagnosis of Stage IIIB Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): E. Topkan
- Abstract
Loading... -
+
P1.09-015 - Impact of Pretretment Leukocytosis on Prognosis in Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy
09:30 - 09:30 | Author(s): E. Topkan
- Abstract
Loading... -
+
P1.09-016 - A single arm, multi-center, phase II study of intercalated erlotinib with gemcitabine/cisplatin as neoadjuvant treatment in stage IIIA non-small cell lung cancer (CTONG 1101, NCT01297101): preliminary result
09:30 - 09:30 | Author(s): S. Lu
- Abstract
Loading... -
+
P1.09-017 - Continuous low dose temozolamide in Brain metastasis from Lung cancer
09:30 - 09:30 | Author(s): T. Shahid
- Abstract
Loading... -
+
P1.09-018 - Pemetrexed and carboplatin concomitant with Thoracic Radiotherapy in Treatment of elderly patients with non- squamous Non Small cell lung Cancer (NSCLC): Institutional Experience
09:30 - 09:30 | Author(s): S. Abdelwahab
- Abstract
Loading... -
+
P1.09-019 - Survival analysis and EGFR gene mutation study for locally advanced non-small cell lung cancer in patients treated with curative intention.
09:30 - 09:30 | Author(s): J. Jove
- Abstract
Loading... -
+
P1.09-020 - Clinical guideline adherence in locally advanced non-small cell lung cancer: A south western Sydney perspective
09:30 - 09:30 | Author(s): K.J. Duggan
- Abstract
Loading... -
+
P1.09-021 - Is PET/CT a better tool than CT in response evaluation and follow-up of stage III non-small cell lung cancer after chemoradiotherapy?
09:30 - 09:30 | Author(s): P.F. Yumuk
- Abstract
Loading... -
+
P1.09-022 - A Multicenter, Randomized, Open-label, Phase II Trial of Erlotinibversus Etoposideplus Cisplatinwith Concurrent Radiotherapy in UnresectableStage III Non-smallCell Lung Cancer (NSCLC) with Activating Mutation of Epidermal Growth Factor Receptor (EGFR) in Exon 19 or 21(RECEL, ML28545, NCT01714908)
09:30 - 09:30 | Author(s): L. Xing
- Abstract
Loading...
-
+
P1.10 - Poster Session 1 - Chemotherapy
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 57
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.10-001 - Phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST study)
09:30 - 09:30 | Author(s): K. Yanagihara
- Abstract
Loading... -
+
P1.10-002 - Comparison of the toxicity and efficacy between topotecan- and belotecan-, a new camptothecin analog, monotherapy for small cell lung cancer : A single institutional experience
09:30 - 09:30 | Author(s): B.M. Park
- Abstract
Loading... -
+
P1.10-003 - Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment
09:30 - 09:30 | Author(s): S.B. Yoo
- Abstract
Loading... -
+
P1.10-004 - Exploratory Subset Analysis in African Americans from the PointBreak Study (Randomized Phase 3 Pemetrexed + Carboplatin + Bevacizumab Followed by Maintenance Pemetrexed + Bevacizumab Versus Paclitaxel + Carboplatin + Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB/ IV Nonsquamous Non-Small Cell Lung Cancer)
09:30 - 09:30 | Author(s): C. Reynolds
- Abstract
Loading... -
+
P1.10-005 - Bevacizumab (Bv) can be safely administered in pts aged > 80 years old
09:30 - 09:30 | Author(s): K.N. Syrigos
- Abstract
Loading... -
+
P1.10-006 - Examination of recurrence predictors in cases receiving UFT as postoperative adjuvant chemotherapy for lung cancer
09:30 - 09:30 | Author(s): K. Nawa
- Abstract
Loading... -
+
P1.10-007 - Biweekly Cisplatin And Gemcitabine As First-Line Treatment in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): M. Benekli
- Abstract
Loading... -
+
P1.10-008 - Clinical Significance of Hyperpigmentation due to Pemetrexed Treatment in Advanced Non-Squamous Non-small cell lung cancer in China
09:30 - 09:30 | Author(s): Q. Hu
- Abstract
Loading... -
+
P1.10-009 - Comparison of Chemotherapy Effect between Cisplatin-Etoposide and Cisplatin-Docetaxel in 2-year Survival Rate and Progression Free Survival Rate of Advanced Non-Small Cell Lung Cancer Patients
09:30 - 09:30 | Author(s): N. Sutandyo
- Abstract
Loading... -
+
P1.10-010 - Survival outcome assessed by response and tumor shrinkage pattern in non-small cell lung cancer patients with activating mutations of the epidermal growth factor receptor
09:30 - 09:30 | Author(s): M. Takeda
- Abstract
Loading... -
+
P1.10-011 - Clinicopathological analysis of long-term (more than 2 years) progression-free survivors treated with epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR mutation-positive non-small cell lung cancer
09:30 - 09:30 | Author(s): M. Morise
- Abstract
Loading... -
+
P1.10-012 - Activity of S-1 for non-small cell lung cancer pretreated with or without pemetrexed.
09:30 - 09:30 | Author(s): Y. Takagi
- Abstract
Loading... -
+
P1.10-013 - Nab-paclitaxel (Abraxane) based chemotherapy for pretreated elderly advanced NSCLC patients: an open-label, single center, randomized phase II trial
09:30 - 09:30 | Author(s): L. Lin
- Abstract
Loading... -
+
P1.10-014 - BIA-6: A novel Akt inhibitor with potent activity in lung cancer
09:30 - 09:30 | Author(s): S.S. Dinavahi
- Abstract
Loading... -
+
P1.10-015 - Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status
09:30 - 09:30 | Author(s): Y. Takeuchi
- Abstract
Loading... -
+
P1.10-016 - TULUNG registry: Analysis of data from PS 0-1 patients with advanced/metastatic non-squamous NSCLC (adenocarcinoma, large cell carcinoma) treated in second line with pemetrexed
09:30 - 09:30 | Author(s): J. Roubec
- Abstract
Loading... -
+
P1.10-017 - Clinical activity of lurbinectedin (PM01183) in combination with gemcitabine (GEM) in non-small cell lung cancer (NSCLC) patients (pts): preliminary subgroup analysis of a phase Ib study.
09:30 - 09:30 | Author(s): L. Paz-Ares
- Abstract
Loading... -
+
P1.10-018 - nab-Paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC): analysis of peripheral neuropathy
09:30 - 09:30 | Author(s): H. Sakai
- Abstract
Loading... -
+
P1.10-019 - Differential efficacy of EGFR-TKI according to variants of exon 19 deletional mutation in non-small cell lung cancer
09:30 - 09:30 | Author(s): T. Kaneda
- Abstract
Loading... -
+
P1.10-020 - Dose adjustment of single agent amrubicin in lung cancer patients with impaired hepatic function
09:30 - 09:30 | Author(s): T. Takahashi
- Abstract
Loading... -
+
P1.10-021 - Phase II study of S-1 plus irinotecan for EGFR-mutated non-small cell lung cancer (NSCLC) resistant to both platinum-based chemotherapy and EGFR-TKI: NJLCG0804
09:30 - 09:30 | Author(s): A. Inoue
- Abstract
Loading... -
+
P1.10-022 - Central European Initiative against Lung Cancer: Results of the Inaugural Workshop
09:30 - 09:30 | Author(s): R. Pirker
- Abstract
Loading... -
+
P1.10-023 - Favorable response to EGFR-TKI is a predictive marker of taxane activity, but not of pemetrexed in patients with non-squamous non-small cell lung cancer
09:30 - 09:30 | Author(s): S.H. Jang
- Abstract
Loading... -
+
P1.10-024 - Clinical features of early interruption of EGFR-TKIs in unselected non small cell lung cancer patients
09:30 - 09:30 | Author(s): T. Jang
- Abstract
Loading... -
+
P1.10-025 - Randomized phase II trial of Safety of Biweekly Docetaxel/Cisplatin vs Gemcitabine/Cisplatin as first-line therapy for advanced non-small cell lung cancer patients who are elderly or poor performance status
09:30 - 09:30 | Author(s): H.K. Kim
- Abstract
Loading... -
+
P1.10-026 - Validation of EGFR Mutation Testing Using Cytology Specimens in Non-small Cell Lung Carcinoma: Multi-institutional study of 128 cases in Korea
09:30 - 09:30 | Author(s): K. Min
- Abstract
Loading... -
+
P1.10-027 - A Phase II Trial of Genexol-PM(a Cremophor-free, polymeric micelle formulation of paclitaxel) and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer.
09:30 - 09:30 | Author(s): E.K. Cho
- Abstract
Loading... -
+
P1.10-028 - A Phase II Trial of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced EGFR Wild-Type and EGFR FISH-Positive Lung Adenocarcinoma
09:30 - 09:30 | Author(s): S. Wang
- Abstract
Loading... -
+
P1.10-029 - An analysis of the drug-drug interaction between docetaxel and gefitinib in patients with advanced non-small cell lung cancer
09:30 - 09:30 | Author(s): M. Motonaga
- Abstract
Loading... -
+
P1.10-030 - Comparative Pharmacokinetics of Two Formulations of Pemetrexed in Indian Adult Chemo-Naive, Adenocarcinoma Non-Small Cell Lung Cancer Patients.
09:30 - 09:30 | Author(s): K.V. Kavathiya
- Abstract
Loading... -
+
P1.10-031 - Platinum-based Therapy with Gemcitabine or Docetaxel in Advanced Non-Small Cell Lung Cancer: A retrospective analysis to evaluate differences in response due to Ethnicity
09:30 - 09:30 | Author(s): Q. Chowdhury
- Abstract
Loading... -
+
P1.10-032 - Sensitivity and meta-regression analysis exploring potential outcomes predictors in randomized trials (RCTs) evaluating the benefit of 1st-line tyrosine kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma.
09:30 - 09:30 | Author(s): S. Pilotto
- Abstract
Loading... -
+
P1.10-033 - Safety and Resource Use in PRONOUNCE: A randomized, phase 3, open-label study of Pemetrexed plus Carboplatin with maintenance Pemetrexed (PemC) and Paclitaxel plus Carboplatin plus Bevacizumab with maintenance Bevacizumab (PCB) in patients with advanced non-squamous (NS) non-small-cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): H.J. Ross
- Abstract
Loading... -
+
P1.10-034 - Weight Gain as a Prognostic Factor on Patient Outcomes
In Advanced, Nonsquamous, Non-small Cell Lung Cancer09:30 - 09:30 | Author(s): J.D. Patel
- Abstract
Loading... -
+
P1.10-035 - Effectiveness of bevacizumab in patients with lung adenocarcinoma treated with pemetrexed / carboplatin as first-line chemotherapy
09:30 - 09:30 | Author(s): M.E. Magallanes
- Abstract
Loading... -
+
P1.10-036 - Prolongation of overall survival in non-small cell lung cancer before and after Food and Drug Administration (FDA) approval of active second line agents: a meta-analysis
09:30 - 09:30 | Author(s): M.J. Fidler
- Abstract
Loading... -
+
P1.10-037 - A retrospective comparison of adjuvant chemotherapeutic regimen for non-small cell lung cancer (NSCLC): Paclitaxel plus platinum versus Vinorelbine plus Cisplatin
09:30 - 09:30 | Author(s): W.J. Chang
- Abstract
Loading... -
+
P1.10-038 - A phase II trial of the combination of gemcitabine and carboplatin as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. (Kenbyo 0601)
09:30 - 09:30 | Author(s): M. Muraoka
- Abstract
Loading... -
+
P1.10-039 - Characteristics of re-biopsied NSCLC patients with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
09:30 - 09:30 | Author(s): D. Arai
- Abstract
Loading... -
+
P1.10-040 - Lung cancer outcomes in an era of more options - Survival analysis from an Asian cancer center
09:30 - 09:30 | Author(s): W. Ong
- Abstract
Loading... -
+
P1.10-041 - A phase II trial of erlotinib for previously treated Japanese patients with advanced non-small cell lung cancer harboring EGFR mutations: results of the Central Japan Lung Study Group trial (CJLSG0904).
09:30 - 09:30 | Author(s): T. Hase
- Abstract
Loading... -
+
P1.10-042 - Chemotherapy in advanced non-small cell lung cancer patients previously treated with adjuvant chemotherapy
09:30 - 09:30 | Author(s): M. Valdes
- Abstract
Loading... -
+
P1.10-043 - Doublet combination of platinum with pemetrexed for advanced non-small-cell lung cancer: a retrospective analysis of a single institution
09:30 - 09:30 | Author(s): S. Ponce Aix
- Abstract
Loading... -
+
P1.10-044 - nab-Paclitaxel in combination with carboplatin as first-line therapy in diabetic patients with advanced non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): V. Hirsh
- Abstract
Loading... -
+
P1.10-045 - Validation Study of Postoperative Platinum-based Adjuvant Chemotherapy for Japanese Patients with Completely Resected Pathological StageIIIA Non-small Cell Lung Cancer
09:30 - 09:30 | Author(s): K. Shiomi
- Abstract
Loading... -
+
P1.10-046 - Heat shock protein 70 as a predictive maker in patients with platinum-based adjuvant chemotherapy in resected non-small cell lung cancer
09:30 - 09:30 | Author(s): T.S. Park
- Abstract
Loading... -
+
P1.10-047 - Clinical Factors Associated with the Efficacy of Pemetrexed as Continuation Maintenance Chemotherapy in Patients with Advanced Lung Adenocarcinoma
09:30 - 09:30 | Author(s): C. Chen
- Abstract
Loading... -
+
P1.10-048 - Real-world evidence for clinical effectiveness, toxicity, and hospitalization costs associated with second-line chemotherapy in Chinese patients with advanced non-squamous non-small cell lung cancer
09:30 - 09:30 | Author(s): C.P. Hu
- Abstract
Loading... -
+
P1.10-049 - Efficacy of bevacizumab combined with paclitaxel and carboplatin: A second line treatment of elderly patients with advanced non-small cell carcinoma (NSCLC)
09:30 - 09:30 | Author(s): S. Abdelwahab
- Abstract
Loading... -
+
P1.10-050 - Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high risk patients with unresectable non-small cell lung cancer
09:30 - 09:30 | Author(s): G. Lee
- Abstract
Loading... -
+
P1.10-051 - Pemetrexed maintenance treatment in advanced non squamous Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): A. Megaiz
- Abstract
Loading... -
+
P1.10-052 - Influence of the epidermal growth factor receptor gene mutation subtypes to the prognosis of the patients with non-small cell lung cancer
09:30 - 09:30 | Author(s): K. Hirai
- Abstract
Loading... -
+
P1.10-053 - Sodiumselenite as a treatment against cancer. A phase I study.
09:30 - 09:30 | Author(s): O. Brodin
- Abstract
Loading... -
+
P1.10-054 - Reduction levels of Carcinoembryonic antigen as a predictive factor of response to chemotherapy in lung cancer patients with Advanced Non-small-cell lung cancer.
09:30 - 09:30 | Author(s): O. Arrieta
- Abstract
Loading... -
+
P1.10-055 - Treatment rationale and study design for an open-label randomized phase II trial of gemcitabine and cisplatin with or without bevacizumab in EGFR wild-type non-squamous non-small-cell lung cancer
09:30 - 09:30 | Author(s): J. Li
- Abstract
Loading... -
+
P1.10-056 - The Elderly Patient Individualized Chemotherapy Trial (EPIC): A Randomized Phase III Multicenter Trial of Customized Chemotherapy versus Standard of Care for 1st Line Treatment of Elderly Patients with Advanced Non-Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): T. Vavala'
- Abstract
Loading... -
+
P1.10-057 - Addition of Custirsen, a Clusterin (CLU) Inhibitor, to Docetaxel in Stage IV Non-Small Cell Lung Cancer (NSCLC): Design of the ENSPIRIT Phase 3 Study
09:30 - 09:30 | Author(s): J. Von Pawel
- Abstract
Loading...
-
+
P1.11 - Poster Session 1 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 45
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.11-001 - Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) related interstitial lung disease in Taiwanese patients with non-small cell lung cancer
09:30 - 09:30 | Author(s): C. Chiang
- Abstract
Loading... -
+
P1.11-002 - Toxicity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): A Meta-analysis
09:30 - 09:30 | Author(s): P.N. Ding
- Abstract
Loading... -
+
P1.11-003 - Exon 19 deletions, smoking history and gender as additional predictive factors for treatment benefit with EGFR Tyrosine Kinase Inhibitors in patients harbouring activating EGFR mutations: A Meta-analysis of 1432 patients in six randomised trials.
09:30 - 09:30 | Author(s): P.N. Ding
- Abstract
Loading... -
+
P1.11-004 - Phase II study of carboplatin-docetaxel-bevacizumab as front-line treatment in patients with stage IV non-squamous non-small-cell lung cancer. Analysis of the bevacizumab (BVZ) maintenance population
09:30 - 09:30 | Author(s): M. Domine
- Abstract
Loading... -
+
P1.11-005 - EVEREST Study: Evolution of disease-related symptoms of patients (p) with advanced non-small cell lung cancer (NSCLC) and its correlation with response to first-line (1L) treatment.
09:30 - 09:30 | Author(s): M. Domine
- Abstract
Loading... -
+
P1.11-006 - Tyrosine kinase inhibitors versus chemotherapy in patients with metastatic Non-Small Cell Lung Cancer harboring EGFR mutation: Venezuelan experience
09:30 - 09:30 | Author(s): G.A. Oblitas
- Abstract
Loading... -
+
P1.11-007 - Phase I study of the ALK inhibitor LDK378 in Japanese patients with advanced, ALK-rearranged NSCLC and other tumors harboring genetic ALK alterations
09:30 - 09:30 | Author(s): T. Seto
- Abstract
Loading... -
+
P1.11-009 - An open label, multicenter, prospective non-interventional (NIS) post-authorization study to monitor the routine clinical practice of Bevacizumab in addition to platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC) in Germany
09:30 - 09:30 | Author(s): C. Schumann
- Abstract
Loading... -
+
P1.11-010 - Physical Targeting of Locally Advanced Non-Small Cell Lung Cancer (NSCLC): Proton Therapy
09:30 - 09:30 | Author(s): J.D. Cox
- Abstract
Loading... -
+
P1.11-011 - Observational study of treatment of epidermal growth factor receptor activating mutation positive (EGFRm+) advanced or recurrent non-small-cell lung cancer (NSCLC), after radiological progression to the first-line therapy with EGFR tyrosine kinase inhibitors (EGFR-TKI).
09:30 - 09:30 | Author(s): H. Kunitoh
- Abstract
Loading... -
+
P1.11-012 - Clinical observation from the treatment of icotinib for 196 cases with advanced non-small cell lung cancer
09:30 - 09:30 | Author(s): Q.A. Gu
- Abstract
Loading... -
+
P1.11-013 - Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic
09:30 - 09:30 | Author(s): J. Skrickova
- Abstract
Loading... -
+
P1.11-014 - Outcome of Metastatic NSCLC patients treated at Windsor Regional Hospital Cancer Program Over 7 years
09:30 - 09:30 | Author(s): S. Kulkarni
- Abstract
Loading... -
+
P1.11-015 - The prognostic value of total number of harvested lymph nodes and nodal ratio in node positive Non-small cell lung cancer
09:30 - 09:30 | Author(s): J. Kim
- Abstract
Loading... -
+
P1.11-016 - A Prospective, Multi-center Phase II Trial on the Efficacy and Safety of Low-dose Erlotinib Monotherapy for Patients with EGFR Mutation-positive, Previously Treated Non-small Cell Lung Cancer: Results of Thoracic Oncology Research Group (TORG) Trial 0911.
09:30 - 09:30 | Author(s): K. Yamada
- Abstract
Loading... -
+
P1.11-017 - First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901
09:30 - 09:30 | Author(s): K. Takahashi
- Abstract
Loading... -
+
P1.11-019 - Phase 2 double-blind, placebo-controlled study of three-weekly farletuzumab with a platinum containing doublet in subjects with previously untreated folate receptor alpha (FRA) expressing non-small-cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): J.D. Maltzman
- Abstract
Loading... -
+
P1.11-020 - Economic Analysis of TORCH: Erlotinib versus Cisplatin and Gemcitabine as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): C. Chung
- Abstract
Loading... -
+
P1.11-021 - First-line erlotinib versus cisplatin/gemcitabine (GP) in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC): interim analyses from the phase 3, open-label, ENSURE study
09:30 - 09:30 | Author(s): Y. Wu
- Abstract
Loading... -
+
P1.11-022 - Retrospective Longitudinal Chart Review of Patients with Advanced Non-Small Cell Lung Cancer in the Netherlands: A Quantification of Disease Burden
09:30 - 09:30 | Author(s): R. Zaim
- Abstract
Loading... -
+
P1.11-023 - Molecular Screening in Advanced Non-Small Cell Lung Cancer: A Systematic Review of Cost-Effectiveness Analyses for First-Line Therapy
09:30 - 09:30 | Author(s): R. Zaim
- Abstract
Loading... -
+
P1.11-024 - A phase I/II randomized trial using GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) vaccine plus or minus CCL21 in stage IV lung adenocarcinoma: Updated results
09:30 - 09:30 | Author(s): J.E. Gray
- Abstract
Loading... -
+
P1.11-025 - EGFR mutation status in adenocarcinoma lung: A single centre experience from Northern India
09:30 - 09:30 | Author(s): J. Wadhwa
- Abstract
Loading... -
+
P1.11-026 - Final Results of a Phase 2 Trial of the Oncolytic Virus Reovirus Serotype 3-Dearing Strain (REOLYSIN®) in Metastatic NSCLC Patients with a Ras-activated Pathway.
09:30 - 09:30 | Author(s): M. Villalona-Calero
- Abstract
Loading... -
+
P1.11-027 - Phase I studies of HM781-36B, an irreversible pan-HER tyrosine kinase inhibitor (TKI) in patients with advanced solid tumor and the therapeutic potential in patients with advanced non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): D. Kim
- Abstract
Loading... -
+
P1.11-028 - Antitumor and immune-biological activity of a new metronomic chemotherapy with fractioned cisplatin and oral etoposide combined with bevacizumab (mPEBev) followed by erlotinib maintenance in non small cell lung cancer (NSCLC) patients
09:30 - 09:30 | Author(s): P. Correale
- Abstract
Loading... -
+
P1.11-029 - The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
09:30 - 09:30 | Author(s): B.T. Li
- Abstract
Loading... -
+
P1.11-030 - Transaminitis induced by epidermal growth factor receptor tyrosine kinase inhibitor predicts for favourable outcome in EGFR mutation positive non-small cell lung cancer
09:30 - 09:30 | Author(s): J.K.H. Ang
- Abstract
Loading... -
+
P1.11-031 - Cost effectiveness analysis between Gefitinib and Erlotinib in the treatment of advanced /metastatic Non small cell lung cancer in Thailand by Payer's perspective: Six years data follow up
09:30 - 09:30 | Author(s): S. Jaruhathai
- Abstract
Loading... -
+
P1.11-033 - Afatinib in EGFR mutant non-small-cell lung cancer patients with acquired resistance to reversible EGFR-TKIs
09:30 - 09:30 | Author(s): F. Cappuzzo
- Abstract
Loading... -
+
P1.11-035 - Outcomes of Afatinib-Based Regimens for Salvage Treatment of Advanced Stage Non-Small Cell Lung Cancer (NSCLC) Patients Who Had Been Heavily Pretreated
09:30 - 09:30 | Author(s): C. Tsai
- Abstract
Loading... -
+
P1.11-036 - The efficacy and safety of sunitinib in EGFR-TKI pretreated advanced non-small cell lung cancer: a retrospective review from Chinese patients at a single institution
09:30 - 09:30 | Author(s): L. Jiang
- Abstract
Loading... -
+
P1.11-037 - Phase II activity of the HSP90 inhibitor AUY922 in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): F. Barlesi
- Abstract
Loading... -
+
P1.11-038 - The significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK target therapy
09:30 - 09:30 | Author(s): N. Zhang
- Abstract
Loading... -
+
P1.11-039 - A randomized phase II trial of celecoxib combined with platinum-based chemotherapy as first-line and with icotinib as second-line treatment for advanced non-small cell lung cancer
09:30 - 09:30 | Author(s): T. Chu
- Abstract
Loading... -
+
P1.11-040 - Treatment strategies after failure to reversible Tyrosine Kinase Inhibitors (rTKI) in EGFR mutant (mut) Non-Small Cell Lung Cancer (NSCLC) patients (p). A retrospective analysis of 59 Spanish Patients
09:30 - 09:30 | Author(s): J. Remon
- Abstract
Loading... -
+
P1.11-041 - Overall survival of ALK translocation - and of EGFR mutation positive NSCLC patients treated with and without personalized therapy. A retrospective analysis within the Network Genomic Medicine
09:30 - 09:30 | Author(s): M. Bos
- Abstract
Loading... -
+
P1.11-042 - SORAVE: Sorafenib and everolimus for patients with solid tumors and with KRAS mutated NSCLC - results of a phase I study.
09:30 - 09:30 | Author(s): L. Nogova
- Abstract
Loading... -
+
P1.11-043 - BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination.
09:30 - 09:30 | Author(s): M. Scheffler
- Abstract
Loading... -
+
P1.11-044 - Progression-free survival is a poor surrogate endpoint for overall survival in the first line EGFR-TKI treatment in advanced non-small-cell lung cancer with EGFR mutation
09:30 - 09:30 | Author(s): R. Liao
- Abstract
Loading... -
+
P1.11-045 - Cost-Effectiveness of Carboplatin and Pemetrexed Versus Single Agent Pemetrexed in Patients with Advanced NSCLC and Performance Status of 2 (PS2)
09:30 - 09:30 | Author(s): C.G. Ferreira
- Abstract
Loading... -
+
P1.11-046 - Women with lung cancer harboring epidermal growth factor (EGFR) mutations: prevalence, clinical characteristics and EGFR tyrosine kinase (TKI) treatment-related outcomes. Results from the Spanish WORLD07 database
09:30 - 09:30 | Author(s): E. Felip
- Abstract
Loading... -
+
P1.11-047 - Management and outcome of Stage IV Non-small Cell Lung Cancer
in a French department between 1998 and 2005 : the role of modern chemotherapy schemes and of the advent of targeted therapies09:30 - 09:30 | Author(s): O. Carpentier
- Abstract
Loading... -
+
P1.11-048 - A Phase 2 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel (P) and Carboplatin (C) in Patients with Squamous Cell Carcinoma of the Lung
09:30 - 09:30 | Author(s): A.C. Mita
- Abstract
Loading... -
+
P1.11-049 - TSR-011: A Potent Inhibitor of ALK Including Crizotinib-Resistant Mutations in Phase 1-2 Development for ALK+ NSCLC
09:30 - 09:30 | Author(s): G.J. Weiss
- Abstract
Loading...
-
+
P1.12 - Poster Session 1 - NSCLC Early Stage
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 23
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.12-001 - Efficacy of pulmonary resection and gamma knife surgery for non-small cell lung cancer with synchronous brain metastasis
09:30 - 09:30 | Author(s): R. Mitsueda
- Abstract
Loading... -
+
P1.12-002 - The clinicopathological features of resected peripheral squamous cell carcinomas of the lung: Prognostic impact of vascular and pleural invasion
09:30 - 09:30 | Author(s): T. Kinoshita
- Abstract
Loading... -
+
P1.12-003 - Preoperative neutrophil and lymphocyte counts are independent prognostic factors in completely resected non-small cell lung cancer
09:30 - 09:30 | Author(s): N. Kobayashi
- Abstract
Loading... -
+
P1.12-004 - Accuracy of PET/CT in the Evaluation of N1 and N2 Lymph Node Stations in Operable NSCLC
09:30 - 09:30 | Author(s): F. Kutluhan
- Abstract
Loading... -
+
P1.12-005 - Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer
09:30 - 09:30 | Author(s): Z. Lin
- Abstract
Loading... -
+
P1.12-006 - Predictive risk factors for mediastinal lymph node metastasis in patients with clinical stage I adenocarcinoma of the lung
09:30 - 09:30 | Author(s): G.D. Lee
- Abstract
Loading... -
+
P1.12-007 - The Predictors of Early Recurrence in Patients with Completely Resected p-stage I Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): K. Hata
- Abstract
Loading... -
+
P1.12-008 - The effects of different preoperative brain survey strategy on the pathological stage I non-small cell lung cancer patients
09:30 - 09:30 | Author(s): C. Tu
- Abstract
Loading... -
+
P1.12-009 - Oral vinorelbine in combination with cisplatin or carboplatin in adjuvant chemotherapy of non-small cell lung cancer: a prospective multicentre study of tolerability and survival.
09:30 - 09:30 | Author(s): V. Kolek
- Abstract
Loading... -
+
P1.12-010 - Lung cancer clinicians' preferences for adjuvant chemotherapy (ACT) in non-small-cell lung cancer (NSCLC): what makes it worthwhile?
09:30 - 09:30 | Author(s): S. McLachlan
- Abstract
Loading... -
+
P1.12-011 - Patients' preferences for adjuvant chemotherapy (ACT) in early non-small cell lung cancer (NSCLC): What makes it worthwhile?
09:30 - 09:30 | Author(s): S. McLachlan
- Abstract
Loading... -
+
P1.12-012 - A Comparison of Clinicopathologic Features and Survival Outcomes between the Lung Cancer Patients with Adenocarcinoma and Squamous Cell Carcinoma: Stage I Disease of Squamous Cell Carcinoma is there?
09:30 - 09:30 | Author(s): T. Fukui
- Abstract
Loading... -
+
P1.12-013 - Limited resection for solid non small cell lung cancers provides worse outcome despite of clinical early stage.
09:30 - 09:30 | Author(s): S.W. Sung
- Abstract
Loading... -
+
P1.12-014 - Lymph node disection and mediastinal recurrence in early stage nsclc
09:30 - 09:30 | Author(s): L. Romero Vielva
- Abstract
Loading... -
+
P1.12-015 - Prognostic impact of the amount of tobacco smoking in patients with resected non-small cell lung cancer
09:30 - 09:30 | Author(s): T. Okamoto
- Abstract
Loading... -
+
P1.12-016 - Retrospective study of ALK expression and clinical implications in completely resected non-small cell lung cancer patients in northern Thailand
09:30 - 09:30 | Author(s): A. Tantraworasin
- Abstract
Loading... -
+
P1.12-017 - A phase IB preoperative pharmacokinetic and pharmacodynamic study of everolimus in operable non small cell lung cancer
09:30 - 09:30 | Author(s): T.K. Owonikoko
- Abstract
Loading... -
+
P1.12-018 - Overall Survival and Smoking Status in Resectable Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): L. Spain
- Abstract
Loading... -
+
P1.12-019 - Survival analysis of 106 female patients with completely resected lung adenocarcinoma in Shaanxi province
09:30 - 09:30 | Author(s): Y. Dai
- Abstract
Loading... -
+
P1.12-020 - Cross-sectional Survey on Lobectomy Approach (X-SOLA)
09:30 - 09:30 | Author(s): C. Cao
- Abstract
Loading... -
+
P1.12-021 - Development and validation of a clinical prediction model for N2 lymph node metastasis in stage I non-small cell lung cancer
09:30 - 09:30 | Author(s): K. Chen
- Abstract
Loading... -
+
P1.12-022 - Predictive value of SUV max/invasive size ratio in the subtypes of lung adenocarcinoma
09:30 - 09:30 | Author(s): E. Yi
- Abstract
Loading... -
+
P1.12-023 - Predictive factors of recurrence in lepidic predominant lung adenocarcinoma
09:30 - 09:30 | Author(s): J. Hung
- Abstract
Loading...
-
+
P1.13 - Poster Session 1 - SCLC
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 8
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.13-001 - Clinical activity of lurbinectedin (PM01183) in combination with doxorubicin (DOX) in small cell lung cancer (SCLC) patients (pts): preliminary results of a phase Ib study subpopulation analysis.
09:30 - 09:30 | Author(s): M. Forster
- Abstract
Loading... -
+
P1.13-002 - Prognostic Value of 18F-fluorodeoxyglucose Uptake in Small Cell Lung Cancer Patients Treated with Concomitant Chemo-radiotherapy or Chemotherapy alone
09:30 - 09:30 | Author(s): K.H. Tran
- Abstract
Loading... -
+
P1.13-003 - Impact of pre-treatment serum lactate dehydrogenase on survival in patients with small cell lung cancer.
09:30 - 09:30 | Author(s): H.S. Takhar
- Abstract
Loading... -
+
P1.13-004 - The heterogeneous phenotype of large-cell neuroendocrine pulmonary carcinoma (LCNEC): A clinico-pathological single institution series.
09:30 - 09:30 | Author(s): H. Biran
- Abstract
Loading... -
+
P1.13-005 - Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer Group experience.
09:30 - 09:30 | Author(s): F.J. Afonso-Afonso
- Abstract
Loading... -
+
P1.13-006 - Phase I/IIa study of the novel combination of bendamustine plus irinotecan followed by etoposide plus carboplatin in untreated patients with extensive stage small cell lung cancer
09:30 - 09:30 | Author(s): S.C. Grant
- Abstract
Loading... -
+
P1.13-007 - The Clinical Impact of Sum of the Maximum Standardized Uptake Value on pretreatment 18F-FDG-PET/CT in Small Cell Lung Cancer treated with Front-line platinum based chemotherapy
09:30 - 09:30 | Author(s): G. Lee
- Abstract
Loading... -
+
P1.13-008 - Omitting elective nodal irradiation and irradiating post-induction versus pre-induction chemotherapy tumor extent for limited-stage small cell lung cancer: an update of a prospective randomized trial
09:30 - 09:30 | Author(s): M. Chen
- Abstract
Loading...
first
prev
